Charles River Laboratories heads into the final quarter of 2026 with the Street firmly in its corner, shorts retreating, and a November earnings date to circle on the calendar.
The analyst story this week has been unusually concentrated and unusually bullish. UBS reinstated coverage on Wednesday with a Buy rating and a $357 target, the highest fresh print on the stock. That followed a wave of target-price raises on Thursday last week, when Jefferies lifted to $340, Barclays to $330, Evercore ISI to $330, Baird to $334, TD Cowen to $325, RBC Capital to $322, and Deutsche Bank to $320. Every firm that moved kept its positive rating. The lone holdout is Mizuho at Neutral, though even it raised its target to $295. The consensus rating is Buy, the mean target has moved above $305, and the analyst recommendation score ranks in the 93rd percentile of the broader universe. That is not a market where the Street is hedging. The implied upside from consensus is modest at current prices, but the directional message is clear: the September 24 print has reset expectations higher across the board.
That print was notable. The stock gained 5.6% on the day. The prior quarter's result was even more dramatic, a 13.4% one-day move that extended to 21.5% over the following five sessions. Charles River has a recent history of delivering meaningful positive earnings surprises, and the 12-month forward EPS year-on-year growth score ranks in the 73rd percentile, reflecting an improving earnings trajectory. The bull case centres on growth and margin targets through 2030, with EPS estimates and targets rising. Bears point to the company's reliance on animal testing and the regulatory and ethical risks if the FDA accelerates acceptance of non-animal methods, alongside the broader contract research industry's sensitivity to government funding shifts.
Shorts have been unwinding through September in a way that reads as covering rather than conviction building. Short interest as a percentage of the float fell nearly 28% over the past month, coming down from roughly 3.1 million shares in mid-August to around 2.2 million now, 4.5% of free float. Cost to borrow is just 0.44%, a low-grade borrow that costs shorts almost nothing to maintain, but the steady exit from positions coincides directly with the earnings beat and the analyst reset. Availability in the lending pool is exceptionally loose at 1,571%, meaning there are roughly fifteen shares available to lend for every one already borrowed. The 52-week availability low was 387%, so the current level represents the easiest borrow conditions the stock has seen all year. Options positioning is equally unthreatening. The put/call ratio is 0.47, close to its 20-day average of 0.45 and less than a quarter of a standard deviation above it. There is no meaningful hedging or defensive positioning in the options market.
On ownership, FMR (Fidelity) recently added to its position and now holds 10.1% of shares outstanding, the largest single holder. Invesco lifted its stake to 6.2% in an August filing, up from 4.9% previously. T. Rowe Price reported a position of 3.15% as of September 1, having added significantly. No 13D activist is on the register. The activist filings picture is passive throughout, with all major holders operating under Schedule 13G. The insider picture is less clean: the 90-day net is heavily negative at roughly negative $42.6 million in value terms, though most of the activity reflects option exercises paired with same-day sales under pre-arranged 10b5-1 plans. The largest individual transaction on record was James Foster, now a Director, exercising options at $194 and $208 and selling 33,561 shares at $300 on August 25, all under a 10b5-1 plan. Pre-arranged sales are a mechanical feature of executive compensation, not a discretionary read on the stock. CEO Birgit Girshick gifted 528 shares in August, a transaction with no economic signal.
Wikipedia attention, the only alt-data series with enough history to read, is running about 1.3 standard deviations below CRL's own 90-day average as of early September, suggesting retail interest remains subdued despite the post-earnings move. There are no measured leading datasets for revenue, so the alt-data tells a story about attention, not fundamentals.
The next print is November 4. With the Street having just reset targets after the September beat, the November report will be the first test of whether the raised estimates reflect a genuine cycle turn in contract research demand or simply optimism riding a single strong quarter.
See the live data behind this article on ORTEX.
Open CRL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
